Therapeutic potential of monoamine transporter substrates
- PMID: 17017961
- DOI: 10.2174/156802606778249766
Therapeutic potential of monoamine transporter substrates
Abstract
Monoamine transporter proteins are targets for many psychoactive compounds, including therapeutic and abused stimulant drugs. This paper reviews recent work from our laboratory investigating the interaction of stimulants with transporters in brain tissue. We illustrate how determining the precise mechanism of stimulant drug action (uptake inhibitor vs. substrate) can provide unique opportunities for medication discovery. An important lesson learned from this work is that drugs which display equipotent substrate activity at dopamine (DA) and serotonin (5-HT) transporters have minimal abuse liability and few stimulant side-effects, yet are able to suppress ongoing drug-seeking behavior. As a specific example, we describe the development of PAL-287 (alpha-methylnapthylethylamine), a dual DA/5-HT releasing agent that suppresses cocaine self-administration in rhesus monkeys, without the adverse effects associated with older phenylethylamine 5-HT releasers (e.g., fenfluramine) and DA releasers (e.g., amphetamine). Our findings demonstrate the feasibility of developing non-amphetamine releasing agents as potential treatments for substance abuse disorders and other psychiatric conditions.
Similar articles
-
Dopamine/serotonin releasers as medications for stimulant addictions.Prog Brain Res. 2008;172:385-406. doi: 10.1016/S0079-6123(08)00919-9. Prog Brain Res. 2008. PMID: 18772043 Review.
-
Monoamine transporter inhibitors and substrates as treatments for stimulant abuse.Adv Pharmacol. 2014;69:129-76. doi: 10.1016/B978-0-12-420118-7.00004-4. Adv Pharmacol. 2014. PMID: 24484977 Free PMC article. Review.
-
Dual dopamine/serotonin releasers: potential treatment agents for stimulant addiction.Exp Clin Psychopharmacol. 2008 Dec;16(6):458-74. doi: 10.1037/a0014103. Exp Clin Psychopharmacol. 2008. PMID: 19086767 Free PMC article. Review.
-
Development of a rationally designed, low abuse potential, biogenic amine releaser that suppresses cocaine self-administration.J Pharmacol Exp Ther. 2005 Jun;313(3):1361-9. doi: 10.1124/jpet.104.082503. Epub 2005 Mar 10. J Pharmacol Exp Ther. 2005. PMID: 15761112
-
Dual dopamine/serotonin releasers as potential medications for stimulant and alcohol addictions.AAPS J. 2007 Jan 5;9(1):E1-10. doi: 10.1208/aapsj0901001. AAPS J. 2007. PMID: 17408232 Free PMC article. Review.
Cited by
-
Unlocking the Potential of High-Quality Dopamine Transporter Pharmacological Data: Advancing Robust Machine Learning-Based QSAR Modeling.bioRxiv [Preprint]. 2024 Mar 11:2024.03.06.583803. doi: 10.1101/2024.03.06.583803. bioRxiv. 2024. PMID: 38558976 Free PMC article. Preprint.
-
Cell-Based Radiotracer Binding and Uptake Inhibition Assays: A Comparison of In Vitro Methods to Assess the Potency of Drugs That Target Monoamine Transporters.Front Pharmacol. 2020 May 19;11:673. doi: 10.3389/fphar.2020.00673. eCollection 2020. Front Pharmacol. 2020. PMID: 32508638 Free PMC article.
-
Stimulants and Pulmonary Arterial Hypertension: An Update.Adv Pulm Hypertens. 2018;17(2):49-54. doi: 10.21693/1933-088X-17.2.49. Adv Pulm Hypertens. 2018. PMID: 31656550 Free PMC article.
-
CNS-targeting pharmacological interventions for the metabolic syndrome.J Clin Invest. 2019 Aug 5;129(10):4058-4071. doi: 10.1172/JCI129195. eCollection 2019 Aug 5. J Clin Invest. 2019. PMID: 31380808 Free PMC article. Review.
-
Skin Delivery and Irritation Potential of Phenmetrazine as a Candidate Transdermal Formulation for Repurposed Indications.AAPS J. 2019 May 31;21(4):70. doi: 10.1208/s12248-019-0335-9. AAPS J. 2019. PMID: 31152318
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials
